Is multiple sclerosis progression associated with the HLA-DR15 haplotype?
EDSS
HLA-DRB1*15:01
HLA-DRB5*01:01
Multiple sclerosis
progression
Journal
Multiple sclerosis journal - experimental, translational and clinical
ISSN: 2055-2173
Titre abrégé: Mult Scler J Exp Transl Clin
Pays: United States
ID NLM: 101668877
Informations de publication
Date de publication:
Historique:
received:
19
06
2019
revised:
04
11
2019
accepted:
09
11
2019
entrez:
17
12
2019
pubmed:
17
12
2019
medline:
17
12
2019
Statut:
epublish
Résumé
The prevalence of multiple sclerosis is associated with the major histocompatibility complex class II DR15 haplotype HLA-DRB1*15:01∼HLA-DRB5*01:01. To assess whether multiple sclerosis progression is associated with the main susceptibility haplotype HLA-DRB1*15:01∼HLA-DRB5*01:01. Patients ( After follow-up of the consecutive cohort 349 patients were classified as having clinical isolated syndrome and 881 patients as having multiple sclerosis. The susceptibility allele HLA-DRB1*15:01 was more frequent in clinical isolated syndrome (odds ratio 1.56) and multiple sclerosis (odds ratio 3.17) compared to controls. HLA- DRB1*15:01 was the only enriched HLA-DRB1 allele in multiple sclerosis patients. Comparison of clinical characteristics between HLA-DRB1*15:01∼HLA-DRB5*01:01 negative and positive patients with multiple sclerosis showed that baseline EDSS score, disease duration and frequency of the category secondary progressive multiple sclerosis with relapse were increased in the HLA-DRB1*15:01∼HLA-DRB5*01:01 positive group. The study confirmed HLA-DRB1*15:01 and HLA-DRB5*01:01 as the main susceptibility alleles and showed weak indirect evidence for a role in progression of the disease.
Sections du résumé
BACKGROUND
BACKGROUND
The prevalence of multiple sclerosis is associated with the major histocompatibility complex class II DR15 haplotype HLA-DRB1*15:01∼HLA-DRB5*01:01.
OBJECTIVE
OBJECTIVE
To assess whether multiple sclerosis progression is associated with the main susceptibility haplotype HLA-DRB1*15:01∼HLA-DRB5*01:01.
METHODS
METHODS
Patients (
RESULTS
RESULTS
After follow-up of the consecutive cohort 349 patients were classified as having clinical isolated syndrome and 881 patients as having multiple sclerosis. The susceptibility allele HLA-DRB1*15:01 was more frequent in clinical isolated syndrome (odds ratio 1.56) and multiple sclerosis (odds ratio 3.17) compared to controls. HLA- DRB1*15:01 was the only enriched HLA-DRB1 allele in multiple sclerosis patients. Comparison of clinical characteristics between HLA-DRB1*15:01∼HLA-DRB5*01:01 negative and positive patients with multiple sclerosis showed that baseline EDSS score, disease duration and frequency of the category secondary progressive multiple sclerosis with relapse were increased in the HLA-DRB1*15:01∼HLA-DRB5*01:01 positive group.
CONCLUSION
CONCLUSIONS
The study confirmed HLA-DRB1*15:01 and HLA-DRB5*01:01 as the main susceptibility alleles and showed weak indirect evidence for a role in progression of the disease.
Identifiants
pubmed: 31839982
doi: 10.1177/2055217319894615
pii: 10.1177_2055217319894615
pmc: PMC6902395
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2055217319894615Informations de copyright
© The Author(s) 2019.
Références
Neurology. 2014 Nov 4;83(19):1712-8
pubmed: 25298310
Brain. 2013 Jun;136(Pt 6):1783-98
pubmed: 23739916
Neurology. 2012 Aug 7;79(6):538-46
pubmed: 22786591
Hum Immunol. 1994 Jan;39(1):41-8
pubmed: 8181961
Cell. 2018 Nov 29;175(6):1679-1687.e7
pubmed: 30343897
Tissue Antigens. 2009 Jul;74(1):17-21
pubmed: 19392788
Neurology. 2014 Mar 11;82(10):865-72
pubmed: 24500647
Proc Natl Acad Sci U S A. 1989 Sep;86(18):7113-7
pubmed: 2571150
Tissue Antigens. 1991 Apr;37(4):161-4
pubmed: 1926124
Nat Genet. 2013 Nov;45(11):1353-60
pubmed: 24076602
Brain. 2013 Jul;136(Pt 7):2298-304
pubmed: 23757766
Genes Immun. 2011 Apr;12(3):183-90
pubmed: 21179117
Am J Hum Genet. 2005 Sep;77(3):454-67
pubmed: 16080120
Arch Neurol. 2009 Dec;66(12):1531-6
pubmed: 20008659
Autoimmun Rev. 2014 Feb;13(2):178-86
pubmed: 24189284
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Annu Rev Immunol. 2005;23:683-747
pubmed: 15771584
Ann Neurol. 2000 Aug;48(2):211-9
pubmed: 10939572
Mult Scler. 2011 Mar;17(3):344-52
pubmed: 21149397
Tissue Antigens. 1995 Oct;46(4):333-6
pubmed: 8560455
Lancet Neurol. 2010 Jul;9(7):727-39
pubmed: 20610348
Nucleic Acids Res. 2003 Jan 1;31(1):311-4
pubmed: 12520010
Eur J Immunogenet. 1991 Feb-Apr;18(1-2):33-55
pubmed: 2069944
Nucleic Acids Res. 1991 Oct 11;19(19):5444
pubmed: 1681511
J Immunol. 2008 Oct 15;181(8):5473-80
pubmed: 18832704
Nat Genet. 2015 Oct;47(10):1107-1113
pubmed: 26343388
Brain. 2011 Mar;134(Pt 3):653-64
pubmed: 21303861
Am J Hum Genet. 2003 Mar;72(3):710-6
pubmed: 12557126
Tissue Antigens. 2000 Feb;55(2):140-8
pubmed: 10746785
Science. 1976 Sep 24;193(4259):1245-7
pubmed: 1085490
Brain. 2015 Mar;138(Pt 3):632-43
pubmed: 25616667
Tissue Antigens. 1998 Jun;51(6):587-92
pubmed: 9694350
Genes Immun. 2008 Sep;9(6):570-4
pubmed: 18615093